There's trouble at Merck Serono's program for Matuzumab, which is in development for colorectal cancer. Merck KGaA says it is "reconsidering" further development of the therapy after the drug failed to hit its endpoint in a Phase II trial. Merck Serono and Takeda have a joint development pact for the drug, which failed to meet their expectations. More work, though, is being planned for other tumor types.
- check out the release